 |
Prospector
Profile
1220-01
|
| |
| TapImmune, Inc. |
NAICS |
541710 |
| Unit 2, 3590 West 41st Avenue,
Vancouver, British Columbia, Canada V6N 3E6 |
Description |
Biotechnology |
| (604) 264-8274 |
Employees |
0 |
| http://www.tapimmune.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-1.3040 |
| |
Assets |
(mil) |
0.1540 |
| |
Liability |
(mil) |
3.1540 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
TapImmune, Inc. had a net loss of $550,739 for the three months ended September 30, 2007, much higher than the $472,264 net loss incurred during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $2,780,428 net loss, substantially higher than the $921,969 net loss incurred during the nine months ended September 30, 2006. As a result of its recurring losses, the Company has an accumulated deficit of $17,505,184 and stockholder's deficit of $1,320,783 as of September 30, 2007. It also has strained liquidity with $205,216 in total current assets available to pay $1,544,491 in total current liabilities.
|
| |
|
Intellectual Property:
Pursuant to the License Agreement with the University of British Columbia (UBC), the Company acquired the exclusive worldwide license to a portfolio of intellectual property including a Method of Enhancing Expression of MHC Class I Molecules Bearing Endogenous Peptides; Method of Identifying MHC Class I Restricted Antigens Endogenously Processed by a Secretory Pathway; and TAP Vaccines and other filings. [SEC Filing 10-KSB 04-17-07]
|
| |
|
Description:
TapImmune, Inc. specializes in the discovery and development of immunotherapeutics aimed at the treatment of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.
|
| |
|
Officers:
Denis Corin (Pres. & CEO); Patrick A. McGowan (CFO, Sec., Treas. & Dir.); Alan P. Lindsay (Dir.); Glynn Wilson (Dir.)
|
| |
|
Auditor:
Dale Matheson Carr-Hilton Labonte LLP
|
| |
|
Securities:
Common Stock-Symbol TPIM.OB; OTC BB;
23,502,681 common shares outstanding as of November 13, 2007.
|
| |
| |
| |
| return to main page |
|
|
